Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Bio-Rad Introduces Anti-Daratumumab Antibodies

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38.

These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars.

Daratumumab is an anticancer drug that binds to the CD38 protein overexpressed in multiple myeloma cells, leading to immune-mediated apoptosis of the tumor cell. The new range of anti-daratumumab antibodies comprises three fully human IgG1 inhibitory antibodies with varying levels of affinity. The antibodies are ideal for use as surrogate positive controls in anti-drug antibody assays, and for the development of pharmacokinetic bridging ELISAs to measure free drug.

Bio-Rad offers a portfolio of recombinant, monoclonal, nonanimal-derived anti-idiotypic antibodies and drug–target complex binders for the development of highly selective and sensitive assays. These critical reagents enable researchers to develop robust methods in a short timescale and produce translatable and reproducible results. The antibodies are generated using the Human Combinatorial Antibody Libraries (HuCAL®) and CysDisplay®, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents.

“We are pleased to continue the expansion of our range of anti-idiotypic antibodies to support researchers developing novel treatments,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group. “Our recombinant production methods result in batch-to-batch consistency, so researchers can rely on our antibodies to deliver reproducible results over the lifecycle of their bioanalytical assays,” she said.

The anti-daratumumab antibodies are approved for in vitro research purposes and for commercial applications providing in vitro testing services to support preclinical and clinical drug development.

For more information about Bio-Rad’s anti-daratumumab antibodies, please visit here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine